Navigation Links
New Treatments Emerging from Immune and Inflammatory Disease R&D Pipelines
Date:6/19/2012

New York, NY (PRWEB) June 19, 2012

A new syndicated TrendsmemeTM Report: Immune and Inflammatory Diseases has been released by Medmeme, LLC., a global leader in comprehensive, integrated medical and science information database platforms. The report details the trends and potential for drug developers in immune/inflammatory diseases particularly focusing on three key disease indications: RA (rheumatoid arthritis), IBD (inflammatory bowel disease), and SLE (systemic lupus erythematosus). According to the Centers for Disease Control and Prevention (CDC) and the Arthritis Foundation (AF), between 1.3 million and 1.5 million people in the United States have RA. The CDC also reports than mortality rates among RA patients are nearly 2.5 times higher than those in the general population, owing primarily to excess risk of cardiovascular disease, infections, and some cancers. The Medmeme report illustrates that treatment of these three indications commands much of the R&D effort and market in this therapeutic category and represents recent, notable scientific progress. R&D for the three indications also offers a window into issues that are relevant broadly across the category.

Medmeme CEO Mahesh Naithani describes the marketplace: ”The value of the immune/inflammatory disease pharmaceutical markets has been driven by very intense research to characterize pathological factors, which was then translated into development of highly targeted biological therapies. Commercial success has come to the companies and brands that have contributed to this clinical revolution. Just three drugs in this therapeutic area— Amgen/Pfizer’s Enbrel, Johnson & Johnson’s Remicade, and Abbott’s Humira— respectively were the seventh, eighth, and ninth highest selling pharmaceutical brands worldwide in 2010, with combined sales exceeding $18 billion. Need for new treatments and market potential have encouraged many companies to be active such as Roche, Merck, Biogen Idec, AstraZeneca, Eli Lilly, Novartis, Regeneron, GlaxoSmithKline, Astellas, and Sanofi, others too. Another major driver of success in immune/inflammatory disease markets has been company strategies of label expansion into multiple disease areas, particularly for biologics like the TNF-a inhibitors.”

Scientific data from the Medmeme database shows that discussion centering on late-stage RA emerging therapies in medical conference presentations and journal publications increased in 2011. This increase is primarily attributable to novel non-TNF-alpha target drugs such as: AstraZeneca’s fostamatinib, an oral Syk kinase inhibitor, Novartis’s secukinumab, a monoclonal antibody against IL-17A, and Pfizer’s tofacitinib, an oral JAK inhibitor. Of these three frontrunner emerging therapies, Pfizer’s tofacitinib may reach market this year. The drug was submitted for U.S. approval to treat RA at the end of 2011.

The syndicated TrendsmemeTM Report: Immune and Inflammatory Diseases can be purchased separately, or, along with other MedMeme reports in the new series, at discounted pricing. To learn more, contact us, or see our website, http://www.medmeme.com/products/syndicated-reports/reports/trendsmeme-reports.

Medmeme, LLC                                     
Yan Barshay, Executive Vice President                 
+1 212-725-5992                                             
yan(at)medmeme(dot)com    
            or
Ray Wright, Vice President, Sales
+ 1 508-278-4595
rwright(at)medmeme(dot)com

Read the full story at http://www.prweb.com/releases/2012/6/prweb9616233.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Feelings of immaturity accompany alcohol misuse into adulthood; discovery could improve treatments
2. Research May Point to New Obesity Treatments
3. Researchers make promising discovery in pursuit of effective lymphoma treatments
4. Study examines treatments for relieving breathing difficulties among patients with lung effusions
5. LA BioMeds Dr. Patricia Dickson researching treatments for neurodegenerative disorders
6. Pre-op Treatments Boost Survival for Esophageal Cancer Patients: Study
7. 1960s-era anti-cancer drug points to treatments for Lou Gehrigs disease
8. Rejuv Medical In Sartell, MN Now Offering Stem Cell Treatments
9. MDS researchers join forces to advance patient treatments and outcomes
10. How does the immune system fight off threats to the brain? New research yields fresh insight
11. Regulatory immune cell diversity tempers autoimmunity in rheumatoid arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... , ... TopConsumerReviews.com recently gave a best-in-class 5 star rating to SpinLife, a ... to people who need help getting around. For some, advancing age has led to ... rehabilitation after an illness or accident. There is a wide variety of scooters, from ...
(Date:12/6/2016)... California (PRWEB) , ... December 06, 2016 , ... "Add ... users to flicker, flash, and flare from clip to clip with high quality 4K ... , TransFlare 4K Jewel contains 44 lens flares filmed on the RED Dragon. Utilizing ...
(Date:12/5/2016)... ... 05, 2016 , ... What: Shriners Hospitals for Children, with the help of ... – using a video monitor and web-enabled camera. Santa visits with children through Dimension ... a Christmas Wonderland, which is where the video connection to the North Pole will ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... Surgery, is excited to announce the arrival of the newest Sciton laser in ... the ability to use tunable non-ablative and ablative wavelengths for exceptional results. Outperforming ...
(Date:12/5/2016)... , ... December 06, 2016 , ... For many years, ... poetry , both thick and thin. The beauty of the Lithuanian language ... Publishing). , In this poetry book, Zubinas lyrically explores all aspects of a living, ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... R.I. , Dec. 5, 2016  CVS Health, ... it has received a perfect score of 100 percent ... consecutive year. The CEI is an annual national benchmarking ... to LGBT equality, administered by the Human Rights Campaign ... the rich diversity that our colleagues, customers and suppliers ...
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, 2016 ... today announced preliminary safety and efficacy data from ... oral selective MDM2 inhibitor, suggesting that DS-3032 may ... relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic ... part of the phase 1 study of DS-3032 were ...
(Date:12/5/2016)... -- John Seng, founder of Spectrum Science Communications , announced today ... Officer following two consecutive years of high double digit growth in ... 2014 and assumed management of the firm that Seng founded in ... Healthcare Agency of the Year and was selected among the Best ... ...
Breaking Medicine Technology: